Protocol Ledger

NCT07175038 · Phase II · RECRUITING

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

Interventional Phase II clinical trial protocol NCT07175038 sponsored by AllRock Bio in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-10-01 Enrollment: 40 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07175038
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)40 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07175038
Protocol FieldVerified Registry Value
NCT IdentifierNCT07175038
Consolidated Lead SponsorAllRock Bio
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment40 participants (ESTIMATED)
Registered Start Date2025-10-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI